Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) had its target price lowered by HC Wainwright from $22.00 to $21.00 in a report issued on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 84.37% from the stock’s previous close.
Several other research firms have also recently commented on LXEO. Chardan Capital restated a “buy” rating and issued a $23.00 target price on shares of Lexeo Therapeutics in a research report on Monday, July 15th. Royal Bank of Canada restated an “outperform” rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday. Baird R W upgraded Lexeo Therapeutics to a “strong-buy” rating in a research report on Thursday, June 13th. Finally, Robert W. Baird began coverage on shares of Lexeo Therapeutics in a research note on Thursday, June 13th. They issued an “outperform” rating and a $28.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $22.14.
Check Out Our Latest Research Report on Lexeo Therapeutics
Lexeo Therapeutics Stock Performance
Insider Buying and Selling at Lexeo Therapeutics
In other news, CEO Richard Nolan Townsend sold 26,969 shares of the company’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $16.50, for a total value of $444,988.50. Following the transaction, the chief executive officer now owns 148,726 shares in the company, valued at approximately $2,453,979. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.50% of the company’s stock.
Institutional Investors Weigh In On Lexeo Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in LXEO. BNP Paribas Financial Markets acquired a new stake in shares of Lexeo Therapeutics in the first quarter worth about $75,000. American International Group Inc. acquired a new stake in Lexeo Therapeutics in the 1st quarter worth approximately $79,000. Rhumbline Advisers boosted its position in Lexeo Therapeutics by 37.3% during the second quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock worth $214,000 after purchasing an additional 3,627 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Lexeo Therapeutics by 12.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company’s stock worth $510,000 after buying an additional 3,483 shares during the period. Finally, Cornell University bought a new position in Lexeo Therapeutics in the 1st quarter worth $1,980,000. 60.67% of the stock is owned by hedge funds and other institutional investors.
Lexeo Therapeutics Company Profile
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
See Also
- Five stocks we like better than Lexeo Therapeutics
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- Dividend Payout Ratio Calculator
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.